ALFA Filings
Every announcement, straight from the exchange
Every IOL Chemicals and Pharmaceuticals earnings call announcement on NSE and BSE, newest first, each with its own page.
Time
5 announcements
IOL Chemicals announced three strategic initiatives involving INR 500 Cr investment: Ibuprofen capacity expansion (to 18,000 MTPA), a new CDMO formulations facility, and a dedicated specialty chemical tolling facility.
IOL delivers a strong Q1FY27 beat driven by a 67% revenue jump in non-ibuprofen APIs and improved operating leverage.
IOLCP reported strong Q1 FY27 results with Revenue at ₹756.3 Cr (up 37.1% YoY) and PAT at ₹64.5 Cr (up 89.9% YoY). The company is strategically shifting towards high-value non-Ibuprofen APIs.
IOL reported record Q4 FY26 revenue of ₹619cr (up 17.4% YoY) and PAT of ₹53cr (up 68% YoY), driven by diversification into non-Ibuprofen APIs and improved chemical segment realization.
IOL reported strong growth in Q4 FY26 with revenue up 17.4% YoY. The company is strategically shifting towards high-value non-Ibuprofen APIs and expanding specialty chemical capacities.